Trial Profile
Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability and Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs MSDC 0160 (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 12 Jun 2012 MR says patient number is 266, but have left as the CT.gov number for now. It definitely appears to be the same trial.
- 09 Jun 2012 Results were presented at the 72nd Scientific Sessions of the American Diabetes Association (ADA), and in a Metabolic Solutions Development Company media release.
- 09 Jun 2012 Primary endpoint 'Fasting-glucose-level' has been met.